Lumos Pharma, Inc.
LUMO
$-0.06
Change (1 day)
$4.55
Year High
$1.37
Year Low
Categories
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare endocrine disorders. The company is headquartered in Austin, Texas.
Lumos Pharma, Inc. (LUMO) - Company Outlook
Company Outlook
| Year | Receivables | Debt | Liabilities | Assets | Current Assets |
|---|---|---|---|---|---|
| 2023 | 210 K | -28,493,000 | 13.33 M | 40.64 M | 40.04 M |
| 2022 | 223 K | -55,774,000 | 12.71 M | 72.29 M | 72.01 M |
| 2021 | 128 K | -94,252,000 | 11.34 M | 100.31 M | 99.68 M |
| 2020 | 26.26 M | -98,360,000 | 12.46 M | 129.03 M | 128.45 M |
| 2019 | 824 K | -89,324,000 | 17.91 M | 96.79 M | 94.42 M |